Enhancing chemotherapy by RNA interference – BIO Integration

Announcing a new article publication for BIO Integration journal. In this review article the authors Shuwen Cao, Chunhao Lin, Shunung Liang, Chee Hwee Tan, Xiaoding Xu and Phei Er Saw from Sun Yatsen University, Guangzhou, China and Guangzhou University of Chinese Medicine, Guangzhou, China consider enhancing chemotherapy by RNA interference.

Small interfering RNA (siRNA) has shown tremendous potential for treating human diseases in the past decades. siRNA can selectively silence a pathological pathway through the targeting and degradation of a specific mRNA, significantly reducing the off-target side effects of anticancer drugs. However, the poor pharmacokinetics of RNA significantly restricted the clinical use of RNAi technology.
In this review, the authors examine in-depth the siRNA therapeutics currently in preclinical and clinical trials, multiple challenges faced in siRNA therapy, feasibility of siRNA treatment with anticancer drugs in combined with siRNA in nanoparticles or modified to be parental drugs, sequential therapy of siRNA treatment prior to drug treatment with siRNA and drugs loaded in nanoparticles. The combinatorial activation of apoptosis by different pathways, namely Bcl-2, survivin, and Pgp protein was focused on. Taken together, this review serves to establish the pathway of effective and efficient combination therapy of siRNA and drugs as a new strategy. BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.
Article reference: Shuwen Cao, Chunhao Lin, Shunung Liang, Chee Hwee Tan, Xiaoding Xu and Phei Er Saw, Enhancing Chemotherapy by RNA Interference. BIO Integration, 2020, https://doi.org/10.15212/bioi-2020-0003

As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.

###

BIOI is now open for submissions; articles can be submitted online at:

https://bio-integration.org/bioiojs/index.php/bioi/login?source=%2Fbioiojs%2Findex.php%2Fbioi%2Fabout%2Fsubmissions

Please visit http://www.bio-integration.org to learn more about the journal.

Editorial Board: https://bio-integration.org/editorial-board/

BIOI is available on the IngentaConnect platform (https://www.ingentaconnect.com/content/cscript/bioi) and at the BIO Integration website (http://www.bio-integration.org).

Submissions may be made using OJS (https://bio-integration.org/bioiojs/index.php/bioi/login?source=%2Fbioiojs%2Findex.php%2Fbioi%2Fabout%2Fsubmissions).

There are no author submission or article processing fees.

Follow BIOI on Twitter @JournalBio https://twitter.com/JournalBio; Facebook (https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and LinkedIn (https://www.linkedin.com/company/bio-integration-journal/).

ISSN 2712-0074

eISSN 2712-0082

Keywords: BIO Integration; chemotherapy, chemotherapeutic enhancement, combination therapy, RNA interference

Media Contact
Morgan Lyons
[email protected]
http://dx.doi.org/10.15212/bioi-2020-0003

Comments